OKYO Net Debt vs Net Working Capital Analysis
| OKYO Stock | USD 1.06 0.01 0.93% |
OKYO Pharma financial indicator trend analysis is much more than just breaking down OKYO Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OKYO Pharma is a good investment. Please check the relationship between OKYO Pharma Net Debt and its Net Working Capital accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Net Debt vs Net Working Capital
Net Debt vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OKYO Pharma Net Debt account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between OKYO Pharma's Net Debt and Net Working Capital is -0.31. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of OKYO Pharma Ltd, assuming nothing else is changed. The correlation between historical values of OKYO Pharma's Net Debt and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of OKYO Pharma Ltd are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Net Debt i.e., OKYO Pharma's Net Debt and Net Working Capital go up and down completely randomly.
Correlation Coefficient | -0.31 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Net Working Capital
Most indicators from OKYO Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OKYO Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At this time, OKYO Pharma's Selling General Administrative is very stable compared to the past year. As of the 16th of December 2024, Tax Provision is likely to grow to about 23.5 K, while Issuance Of Capital Stock is likely to drop about 3.2 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 2.4K | 3.8K | 7.5K | 6.1K | Research Development | 1.6M | 6.3M | 8.2K | 7.8K |
OKYO Pharma fundamental ratios Correlations
Click cells to compare fundamentals
OKYO Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
OKYO Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 597.4K | 7.1M | 4.3M | 5.2M | 1.5M | 1.5M | |
| Total Current Liabilities | 710.7K | 1.7M | 1.4M | 7.3M | 7.4M | 7.8M | |
| Total Stockholder Equity | (139.8K) | 5.3M | 2.9M | (2.1M) | (5.9M) | (5.6M) | |
| Property Plant And Equipment Net | 30.7K | 104.6K | 5.2K | 7.2K | 3.4K | 3.2K | |
| Net Debt | (203.3K) | (6.8M) | (2.7M) | (1.8M) | (826.8K) | (868.2K) | |
| Retained Earnings | (85.9M) | (106.0M) | (112.4M) | (125.7M) | (142.5M) | (135.4M) | |
| Accounts Payable | 593.7K | 211.0K | 517.7K | 1.0M | 4.4M | 4.6M | |
| Cash | 235.0K | 6.9M | 2.7M | 4.0M | 826.8K | 785.5K | |
| Non Current Assets Total | 30.7K | 104.6K | 5.2K | 7.2K | 3.4K | 3.2K | |
| Cash And Short Term Investments | 235.0K | 6.9M | 2.7M | 4.0M | 826.8K | 785.5K | |
| Common Stock Shares Outstanding | 595.5M | 672.8M | 979.2M | 22.3M | 29.3M | 27.9M | |
| Liabilities And Stockholders Equity | 597.4K | 7.1M | 4.3M | 5.2M | 1.5M | 1.5M | |
| Other Current Assets | 6.4K | 97.4K | 711.2K | 171.2K | 130.1K | 111.8K | |
| Other Stockholder Equity | 83.5M | (306.0K) | 2.4M | 3.7M | 4.8M | 4.6M | |
| Total Liab | 737.2K | 1.8M | 1.4M | 7.3M | 7.4M | 7.8M | |
| Total Current Assets | 566.7K | 7.0M | 4.3M | 5.2M | 1.5M | 1.5M | |
| Other Current Liab | 111.9K | 1.5M | 835.5K | 4.4M | 3.0M | 3.2M | |
| Net Receivables | 326.2K | 76.3K | 883.4K | 980.1K | 580.9K | 347.0K | |
| Accumulated Other Comprehensive Income | 2.2M | 12.8M | (11.0M) | (11.5M) | (11.3M) | (10.7M) | |
| Common Stock | 67.5M | 111.6M | 124.0M | 131.4M | 143.1M | 110.9M | |
| Net Tangible Assets | 255.4K | (113.0K) | 3.9M | 2.2M | 2.6M | 1.8M | |
| Net Invested Capital | (113.0K) | 3.9M | 2.9M | 161.9K | (5.9M) | (5.6M) | |
| Capital Stock | 67.5M | 111.6M | 124.0M | 131.4M | 143.1M | 118.4M | |
| Net Working Capital | (116.4K) | 3.8M | 2.9M | (2.1M) | (5.9M) | (5.6M) |
Pair Trading with OKYO Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against OKYO Stock
| 0.38 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.